Stemline Therapeutics, Inc.

The sheer number of US FDA’s novel drug approvals in 2023 contrasts with the generally moderate, steady performance of the Center for Drug Evaluation and Research over the year, including a median rev

While Menarini Group / Stemline Therapeutics, Inc. ’s leading oral selective estrogen receptor degrader (SERD) Orserdu has got off to a strong start following its February launch for breast cancer, n

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Takeda, F-star Sign Joint Research Pact

The US FDA is starting out 2023 with one of the most well-stocked review queue in recent years, with almost 60 new molecular entities and novel biologics applications with user fee goal dates suggesti